Pharmaron completes investment in PharmaGend

Pharmaron Beijing (SZSE:300759) announced the completion of its additional investment in PharmaGend Global Medical Services Pte. Ltd. The investment, executed through its wholly-owned subsidiary Pharmaron (Hong Kong) International Limited, totaled $10.5 million. This follows approvals from the Beijing Municipal Development and Reform Commission and the Beijing Municipal Commerce Bureau. With all preconditions met, the capital injection has been fully paid. As of March 10, 2025, PharmaGend's updated shareholding structure includes Pharmaron (Hong Kong) International Limited with 35% ($28 million), CMS MEDICAL VENTURE PTE. LTD. with 33.8% ($27.04 million), Rxilient Health Pte. Ltd. with 11.2% ($8.96 million), and HEALTHY GOAL LIMITED with 20% ($16 million).